Sai Life Sciences Limited has informed the Exchange regarding Appointment of Mr. Krishnamraju Kanumuri as Managing Director & CEO of the company w.e.f. September 01, 2025.

Management Changes View source PDF Explain this filing

SAILIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.7%Reaction day

₹791.95

prior close

₹815.25

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-1.3%+4.9% vs market

Pharmaceuticals peers, median of 147sector-0.9%+4.5% vs sector

On the reaction day the stock moved 4.9 pts more than Nifty Smallcap 250 and 4.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.9

10m

+2.2

15m

+1.7

30m

+1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.7-1.3+4.9-0.9+4.5

Next day

+11.6-0.8+12.4-0.6+12.2

+10.4-0.8+11.1-0.3+10.6

+14.0-0.2+14.2-0.6+14.6

+12.1-0.6+12.7-0.6+12.7

+13.9+0.7+13.1-0.9+14.8

+15.3+1.9+13.4-0.1+15.4

15d

+3.8+0.5+3.3-0.8+4.6

+7.9+1.1+6.8-1.0+8.9

+8.1+1.2+6.9-1.3+9.4

+14.9+1.6+13.3-4.7+19.6

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sai Life Sciences' board has approved the reappointment of Mr. Krishnamraju Kanumuri as Managing Director & CEO for a five-year term from September 1, 2025 to August 31, 2030, pending shareholder approval at the upcoming AGM. Mr. Kanumuri has been with the company since 2004 and currently leads it — he spearheaded the December 2024 IPO, set up R&D centres in Boston and Manchester, and drove a 25% revenue CAGR between 2022 and 2025. He is the son of Dr. K Ranga Raju, the company's Chairman and Promoter. The reappointment is subject to shareholder approval at the AGM and he is not debarred by any regulatory authority.

Likely market impact

This is a continuity move with no leadership change, generally viewed positively as it signals board confidence in the existing growth strategy. Shareholders should note the reappointment still requires their approval at the AGM, and the promoter-family linkage may attract governance attention from some investors.